Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer

BACKGROUND: The aim of our study was to retrospectively assess the incidence of interstitial lung disease (ILD) related to EGFR‐tyrosine kinase inhibitor (TKI) treatment immediately before and/or after the administration of a PD‐1 antibody. METHODS: We analyzed the data of 26 patients who underwent...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thorac Cancer
Autors principals: Uchida, Takahiro, Kaira, Kyoichi, Yamaguchi, Ou, Mouri, Atsuto, Shiono, Ayako, Miura, Yu, Hashimoto, Kosuke, Nishihara, Fuyumi, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons Australia, Ltd 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6449223/
https://ncbi.nlm.nih.gov/pubmed/30864291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13039
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars